Table of Content

1. Research Methodology


2. Approved CD19 Targeting Therapies


3. Global CD19 Antibodies Market Dynamics
3.1 Current Market Trends & Developments
3.2 Future Growth Avenues


4. CD19 Targeting Therapies Clinical Trials & Market Insight by Indication
4.1 Hematological Cancers
4.1.1 Leukemia
4.1.2 Lymphoma

4.2 Solid Cancers
4.3 Immune System Diseases


5. CD19 Targeting Therapies Market Dynamics by Region
5.1 US
5.2 China
5.3 EU
5.4 Canada
5.5 Australia


6. Global CD19 Market Sales & Price insight By Approved Drugs
6.1 Blincyto - 1st CD19 Targeting Therapy
6.1.1 Overview & Patent Insight
6.1.2 Pricing & Dosage Insight
6.1.3 Sales Analysis


6.2 Kymriah - 1st Anti-CD19 CAR T Cell Therapy
6.2.1 Overview
6.2.2 Pricing & Dosage Insight
6.2.3 Sales Analysis

6.3 Yescarta
6.3.1 Overview & Patent Insight
6.3.2 Pricing & Dosage
6.3.3 Sales Analysis

6.4 Uplizna - 1st Anti-CD19 Monoclonal Antibody
6.4.1 Overview & Patent Insight
6.4.2 Pricing & Dosage
6.4.3 Sales Analysis

6.5 Tecartus
6.5.1 Overview
6.5.2 Pricing & Dosage
6.5.3 Sales Analysis

6.6 Monjuvi
6.6.1 Overview & Patent Insight
6.6.2 Pricing & Dosage
6.6.3 Sales Analysis

6.7 Breyanzi
6.7.1 Overview & Patent Insight
6.7.2 Pricing & Dosage
6.7.3 Sales Analysis

6.8 Zynlonta - 1st CD19-Targeted ADC Therapy
6.8.1 Overview & Patent Insight
6.8.2 Pricing & Dosage
6.8.3 Sales Analysis


6.9 Carteyva
6.9.1 Overview & Patent Insight
6.9.2 Sales Analysis

6.10 NexCAR19 - 1st CD19 Targeting CAR T Cell Therapy


7. Global CD19 Antibodies Clinical Trials Overview
7.1 By Country
7.2 Indication
7.3 Phase
7.4 Therapy Class


8. Global CD19 Antibodies Clinical Trials By Company, Indication & Phase
8.1 Research
8.2 Preclinical
8.3 Phase-I
8.4 Phase-I/II
8.5 Phase-II
8.6 Phase-III
8.7 Preregistration
8.8 Registered


9. Commercially Approved CD19 Antibodies Clinical Insight


10. Competitive Landscape
10.1 AbbVie
10.2 Aleta Biotherapeutics
10.3 Autolus
10.4 Bristol-Myers Squibb
10.5 Cabaret Biotech
10.6 Cellectis
10.7 Cellular Biomedicine Group
10.8 Chongqing Precision Biotech Co., Ltd
10.9 CRISPR Therapeutics
10.10 Eureka Therapeutics
10.11 EXUMA Biotech
10.12 Fate Therapeutics
10.13 Galapagos NV
10.14 Gilead Sciences
10.15 Gracell Biotechnology
10.16 Guangzhou Bio-gene Technology
10.17 Hebei Senlang Biotechnology
10.18 ImmPACT Bio
10.19 Immvira Pharma
10.20 Innovative Cellular Therapeutics
10.21 Juventas Cell Therapy
10.22 Kite Pharma
10.23 Kyverna Therapeutics
10.24 MedTherapy
10.25 Memorial Sloan-Kettering Cancer Center
10.26 Nanjing Bioheng Biotech
10.27 Nanjing IASO Biotherapeutics
10.28 Poseida Therapeutics
10.29 Precision Biosciences
10.30 Sana Biotechnology



List of Tables

Table 2-1: Globally Approved CD19 Targeting Therapies

Table 3-1: Global – CD19 Antibodies Sales By Brand Name (US$ Million), 2019-2023
Table 3-2: Global – CD19 Antibodies Quarterly Sales (US$ Million), 2022

Table 4-1: Hematological Cancers - Approved CD19 Targeting Therapies &
Mechanism of Action
Table 4-2: Immune System Diseases - Approved CD19 targeting therapies &
Mechanism of Action

Table 5-1: US – FDA Designations for CD19 Targeting Therapies, October’2023
Table 5-2: US – FDA IND Applications Accepted for CD19 Targeting Therapies October’2023
Table 5-3: China – NMPA IND Applications Accepted for CD19 Targeting Therapies October’2023

Table 6-1: Blincyto - Recommended Dosage & Schedule for the Treatment of MRD-positive B-cell Precursor ALL
Table 6-2: Blincyto - Recommended Dosage & Schedule for Treatment of Relapsed
or Refractory B-cell Precursor ALL
Table 6-3: Blincyto – Recommended Dose Modifications
Table 6-4: Uplizna - Premedication Prior to Each Infusion
Table 6-5: Monjuvi - Dosing Schedule
Table 6-6: Monjuvi - Dosage Modifications for Adverse Reactions